Can I Take Glutathione with Tadalafil (Generic)?

What Is Tadalafil and How Does It Work?

Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor approved by the FDA in 2003 under the brand name Cialis, with generic versions widely available since 2018 [1]. It works by blocking the enzyme PDE5, which allows cyclic guanosine monophosphate (cGMP) to accumulate in smooth muscle cells. The result is relaxation of vascular and non-vascular smooth muscle, increased blood flow to penile tissue, and reduced smooth-muscle tone in the prostate and bladder neck [2].

Approved Doses and Indications

Tadalafil is approved at:

• 2.5 to 5 mg once daily for erectile dysfunction (ED) or benign prostatic hyperplasia (BPH)
• 10 to 20 mg on demand for ED
• 40 mg once daily (Adcirca brand) for pulmonary arterial hypertension

The majority of men using generic tadalafil from telehealth platforms fall into the 2.5 to 20 mg daily or as-needed category [1].

Tadalafil Metabolism: The CYP3A4 Connection

Tadalafil is metabolized almost entirely by CYP3A4 in the liver [2]. This detail matters for supplement interactions because any compound that inhibits or induces CYP3A4 can raise or lower tadalafil plasma concentrations. The FDA label explicitly warns against combining tadalafil with strong CYP3A4 inhibitors such as ketoconazole and ritonavir [1]. Glutathione does not appear on this list.

What Is Glutathione and Why Do People Take It?

Glutathione is a tripeptide (gamma-L-glutamyl-L-cysteinyl-glycine) synthesized endogenously in every human cell [3]. It is the body's most abundant intracellular antioxidant. People supplement with it for skin-brightening, oxidative stress reduction, liver support, and general anti-aging goals. Forms on the market include oral capsules, sublingual tablets, liposomal liquids, and intravenous (IV) or intramuscular (IM) injections [4].

Oral vs. Injectable Glutathione: A Clinically Relevant Distinction

These two delivery forms behave very differently in the body.

Oral glutathione is largely hydrolyzed in the gastrointestinal tract before reaching systemic circulation. A randomized trial (N=54) published in the European Journal of Nutrition (2015) by Richie et al. Showed that 500 to 1,000 mg/day of oral reduced glutathione for 6 months increased blood and tissue glutathione levels modestly but did not produce clinically significant cardiovascular effects [5].

IV glutathione bypasses first-pass metabolism entirely, delivering intact tripeptide directly to systemic circulation. Concentrations 10 to 100 times higher than oral supplementation are achievable. IV glutathione has vasodilatory properties, documented in a study showing dose-dependent increases in forearm blood flow following intra-arterial administration [6]. This vasodilatory effect is the primary concern when combining with a PDE5 inhibitor.

CYP450 Profile of Glutathione

Glutathione is not a known inhibitor or inducer of any CYP450 isoform at physiological or supplemental doses [3]. The Natural Medicines Database rates the oral glutathione-tadalafil interaction as having "insufficient evidence" for a clinical interaction. No studies published on PubMed document altered tadalafil pharmacokinetics in subjects taking glutathione.

Is There a Pharmacokinetic Interaction Between Glutathione and Tadalafil?

No pharmacokinetic interaction has been identified. Tadalafil is metabolized by CYP3A4 and excreted as inactive metabolites in feces (61%) and urine (36%) [2]. Glutathione does not modulate CYP3A4, CYP2C9, or P-glycoprotein, which are the relevant clearance pathways for tadalafil [3]. Therefore, glutathione is not expected to change tadalafil's peak plasma concentration (Cmax), area under the curve (AUC), or half-life of approximately 17.5 hours.

What the Absence of Evidence Actually Means

Absence of documented interaction is reassuring but not a guarantee of zero risk. Glutathione research as a supplement is still emerging, and no dedicated drug-interaction pharmacokinetic study has evaluated the tadalafil-glutathione pair specifically. Clinicians should treat this as "no known interaction" rather than "proven safe in all circumstances."

Is There a Pharmacodynamic Interaction?

This is the more clinically meaningful question for most patients. Both tadalafil and IV glutathione have vasodilatory properties, creating a theoretical additive hypotensive effect.

Tadalafil and Blood Pressure

Tadalafil alone produces a mean maximum decrease in systolic blood pressure of approximately 8.4 mmHg and diastolic of 5.5 mmHg in healthy volunteers, per the FDA prescribing information [1]. This effect is amplified substantially when tadalafil is combined with nitrates, which is why concurrent nitrate use is contraindicated [1].

IV Glutathione and Vascular Effects

A study by Jain et al. Published in Arteriosclerosis, Thrombosis, and Vascular Biology found that intravenous glutathione infusion increased forearm blood flow by roughly 50% above baseline through a nitric oxide-independent, direct smooth-muscle relaxation pathway [6]. If IV glutathione is administered within hours of a tadalafil dose, additive blood pressure reduction is biologically plausible.

Oral Glutathione and Blood Pressure

Oral glutathione does not reach systemic concentrations high enough to produce measurable vasodilation in published trials [5]. The Richie et al. Trial found no significant change in blood pressure in participants taking oral glutathione at 1,000 mg/day for 6 months [5]. Oral glutathione is therefore not expected to produce a clinically relevant pharmacodynamic interaction with tadalafil.

Liver Detox Concerns: Does Glutathione Affect Tadalafil's Hepatic Clearance?

Glutathione's antioxidant role in the liver is well established. It protects hepatocytes from oxidative damage and supports phase II detoxification by conjugating electrophilic compounds for excretion [3]. Some patients worry that boosting glutathione will alter hepatic drug metabolism and change how tadalafil is processed.

The concern, while logical at first glance, is not supported by evidence. CYP3A4 enzyme activity is regulated separately from glutathione-S-transferase (GST) pathways [7]. A review in Drug Metabolism and Disposition confirmed that glutathione supplementation does not upregulate or downregulate CYP3A4 expression in human liver microsomes [7]. Tadalafil clearance is therefore not expected to be affected.

Hepatic Safety of the Combination

Tadalafil's prescribing information notes that patients with Child-Pugh Class A or B hepatic impairment may use doses up to 10 mg without adjustment, while Class C (severe) hepatic impairment has not been adequately studied [1]. Glutathione is hepatoprotective at supplemental doses and has been studied as an adjunct in non-alcoholic fatty liver disease (NAFLD). A randomized controlled trial (N=29) published in Hepatology Research showed that 300 mg/day of oral glutathione for 4 months significantly reduced ALT and triglyceride levels in NAFLD patients without adverse events [8]. No hepatotoxic interaction with tadalafil is anticipated.

Special Populations and Risk Stratification

The following framework helps clinicians and patients assess their individual risk level when combining tadalafil with glutathione:

Low Risk (no specific action required beyond awareness)

• Oral or liposomal glutathione at standard doses (250 to 1,000 mg/day)
• Tadalafil 2.5 to 20 mg daily or on-demand
• Normal baseline blood pressure (systolic 110 to 139 mmHg)
• No concurrent nitrate, alpha-blocker, or antihypertensive use

Moderate Risk (discuss with prescriber before combining)

• IV or IM glutathione at any dose
• Tadalafil combined with alpha-blockers (e.g., tamsulosin) already causing a blood-pressure-lowering effect
• Baseline systolic blood pressure <110 mmHg
• History of orthostatic hypotension

Higher Risk (prescriber clearance required)

• IV glutathione infusion on the same day as a tadalafil dose in patients with cardiovascular disease
• Patients on nitrates (combination with tadalafil is absolutely contraindicated regardless of glutathione [1])
• Patients with Child-Pugh Class C hepatic impairment

Dose-Separation Guidance

Because the main theoretical risk is additive vasodilation with IV glutathione, timing of administration matters more for injectable forms than for oral supplementation.

Tadalafil 2.5 to 5 mg daily maintains stable plasma levels with a half-life of 17.5 hours, meaning there is no single "off" window [2]. For on-demand tadalafil (10 to 20 mg), peak plasma concentration occurs at approximately 2 hours post-dose and the drug remains above half-maximal plasma levels for roughly 36 hours [1].

If a patient chooses to receive IV glutathione while on daily tadalafil, separating administration by at least 24 hours is a reasonable conservative measure, though no clinical trial has validated a specific window. Oral glutathione requires no dose separation based on available evidence.

What to Do If You Are Already Taking Both

Many patients are already combining oral glutathione with tadalafil before speaking to a clinician. Based on current evidence, this combination at oral glutathione doses is unlikely to have caused harm. The steps below are appropriate:

1. Inform your prescriber. Disclose all supplements at every medication review. A cross-sectional study in JAMA found that 69% of adults do not disclose supplement use to their physicians [9].
2. Monitor blood pressure. Check blood pressure at least once after starting or increasing glutathione dose, particularly if you experience dizziness, lightheadedness, or flushing.
3. Switch to oral forms if using IV glutathione recreationally. Oral glutathione has a more favorable safety profile for concurrent use with PDE5 inhibitors.
4. Report new symptoms promptly. Sudden hypotension, priapism lasting more than 4 hours, or severe headache warrant immediate medical evaluation [1].

Relevant Drug Interactions That Tadalafil Actually Has

To give this safety question proper context, tadalafil's established, clinically significant interactions are worth reviewing. These are the combinations that carry documented risk [1][2]:

• Nitrates (nitroglycerin, isosorbide): Absolute contraindication. Additive cGMP-mediated vasodilation can cause life-threatening hypotension.
• Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin): Increase tadalafil AUC by 2- to 4-fold; dose reduction required.
• Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine): Reduce tadalafil AUC by up to 88%; efficacy may be lost [2].
• Alpha-blockers (tamsulosin, doxazosin): Additive hypotension; start at lowest tadalafil dose and titrate.
• Alcohol at heavy intake (>5 units): Potentiates hypotension.

Glutathione does not fall into any of these categories.

Supplements With More Documented Concern Than Glutathione

Several supplements carry a higher documented interaction concern with tadalafil than glutathione does [10]:

• St. John's Wort (Hypericum perforatum): A potent CYP3A4 inducer. A crossover pharmacokinetic study (N=16) showed it reduced sildenafil AUC by 52%; a similar reduction is expected with tadalafil [10].
• Grapefruit / grapefruit juice: Contains furanocoumarins that inhibit intestinal CYP3A4, raising tadalafil exposure.
• Yohimbe: Sympathomimetic; when combined with a PDE5 inhibitor may cause unpredictable blood pressure swings.

Patients who are concerned about glutathione but currently using St. John's Wort or grapefruit juice regularly should prioritize addressing those interactions first.

What Current Guidelines Say About PDE5 Inhibitor Safety Monitoring

The American Urological Association (AUA) 2018 guideline on erectile dysfunction recommends that clinicians review all concurrent medications and supplements before initiating PDE5 inhibitor therapy [11]. The guideline states: "Clinicians should obtain a detailed medication and supplement history to identify potential drug interactions prior to prescribing PDE5 inhibitors." This does not specifically mention glutathione, reflecting the absence of documented interaction.

The AHA/ACC 2012 scientific statement on the use of phosphodiesterase inhibitors notes that "the hemodynamic effects of PDE5 inhibitors are modest in patients without significant cardiovascular disease" and that monitoring is primarily warranted when combining with any vasodilatory agent [12].

Evidence Quality Summary

The evidence base for this topic has real limitations. Randomized controlled trial data specifically studying tadalafil plus glutathione do not exist. The conclusions in this article rest on:

• Tadalafil pharmacokinetic data from the FDA prescribing label and peer-reviewed trials [1][2]
• Glutathione pharmacokinetic and pharmacodynamic data from human trials [5][6]
• Mechanistic evidence about CYP3A4 and glutathione-S-transferase independence [3][7]
• Extrapolation from related PDE5 inhibitor interaction data [10]

A 2019 systematic review in Clinical Pharmacology and Therapeutics (N=23 studies) confirmed that the evidence base for most dietary supplement-drug interactions remains limited, with fewer than 5% of supplement-drug pairs having RCT-level pharmacokinetic data [13]. The tadalafil-glutathione pair fits this description exactly.

Practical Guidance for Telehealth Patients

Patients receiving tadalafil through a telehealth platform should follow these specific steps at their next check-in:

• Disclose all forms of glutathione being used, including the route (oral, liposomal, IV, IM) and dose
• Report any episodes of dizziness, flushing, or low blood pressure since starting glutathione
• Ask about skin-brightening IV glutathione protocols if they are receiving these treatments at a medspa or infusion clinic concurrently with tadalafil

A 2022 survey published in JAMA Dermatology found that IV glutathione use for skin lightening had increased substantially in South and Southeast Asian communities in the United States, with an estimated 300,000 IV glutathione infusions administered annually in US aesthetics settings [14]. Patients in these demographics who also use tadalafil represent a real clinical overlap that providers should ask about directly.